(S)-5-[(ビフェニル-4-イル)メチル]ピロリジン-2-オン
(S)-5-[(ビフェニル-4-イル)メチル]ピロリジン-2-オン 物理性質
- 沸点 :
- 473.6±24.0 °C(Predicted)
- 比重(密度) :
- 1.117±0.06 g/cm3(Predicted)
- 酸解離定数(Pka):
- 16.31±0.40(Predicted)
安全性情報
(S)-5-[(ビフェニル-4-イル)メチル]ピロリジン-2-オン 価格
もっと(2)
| メーカー |
製品番号 |
製品説明 |
CAS番号 |
包装 |
価格 |
更新時間 |
購入 |
|
富士フイルム和光純薬株式会社(wako)
|
W01COBQM-6499 |
(S)-5-[(ビフェニル-4-イル)メチル]ピロリジン-2-オン
(S)-5-[(Biphenyl-4-yl)methyl]pyrrolidin-2-one |
1038924-61-6 |
250mg |
￥157500 |
2023-06-01 |
購入 |
|
富士フイルム和光純薬株式会社(wako)
|
W01COBQM-6499 |
(S)-5-[(ビフェニル-4-イル)メチル]ピロリジン-2-オン
(S)-5-[(Biphenyl-4-yl)methyl]pyrrolidin-2-one |
1038924-61-6 |
1g |
￥396000 |
2023-06-01 |
購入 |
(S)-5-[(ビフェニル-4-イル)メチル]ピロリジン-2-オン 化学特性,用途語,生産方法
説明
Sacubitril is a neprilysin
inhibitor prodrug developed by Novartis that was approved
as part of an orally administered supramolecular sodium salt
complex with the angiotensin receptor blocker (ARB) valsartan
in the U.S. and EU in 2015. Sacubitril/valsartan (also known
as LCZ-696) is a first-in-class dual angiotensin receptor
blocker neprilysin inhibitor (ARNI) marketed for the treatment
of chronic heart failure with reduced ejection fraction
(HFrEF). It represents a novel mechanistic approach to
targeting HFrEF and is the first pharmacologic agent approved
for HFrEF since 2004. Sacubitril is metabolized by enzymatic
conversion of the ethyl ester to the active diacid (LBQ-657,
structure not disclosed), which inhibits neprilysin and prevents endogenous natriuretic peptide degradation. Neprilysin
inhibitors like sacubitril are not effective as monotherapy and
need to be combined with a reninangiotensin aldosterone
system (RAAS) inhibitor such as valsartan. Notably, dual
neprilysin and angiotensin-converting enzyme (ACE) inhibition,
as in omapatrilat, was found to be associated with an
increased risk of life-threatening angioedema due to increased
bradykinin levels. In phase III clinical trials, sacubitril/
valsartan displayed a superior safety profile to enalapril, with
a 20% decrease in heart failure hospitalizations or cardiovascular
death and a 16% reduction in the risk of death from any
cause. Sacubitril/valsartan is now recommended as the standard
of care for HFrEF as an alternative to ACEs and ARBs.
(S)-5-[(ビフェニル-4-イル)メチル]ピロリジン-2-オン 上流と下流の製品情報
原材料
1-Pyrrolidinecarboxylic acid, 2-([1,1'-biphenyl]-4-ylmethyl)-5-oxo-, 1,1-dimethylethyl ester, (2S)-
(S)-5-(CHLOROMETHYL)PYRROLIDIN-2-ONE
2-Pyrrolidinone, 5-(iodomethyl)-, (5S)-
(S)-5-[(Biphenyl-4-yl)carbonyl]pyrrolidin-2-one
(+)‐P‐トルエンスルホン酸(S)‐5‐(ヒドロキシメチル)‐2‐ピロリジノン
LCZ696 interMediate
(5S)-5β-(ブロモメチル)ピロリジン-2-オン
[ボック]-D-4,4-ビフェニルアラニン
4-ビフェニルマグネシウムブロミド 溶液
2-(4-ビフェニルイル)-4,4,5,5-テトラメチル-1,3,2-ジオキサボロラン
硝酸マグネシウム·6水和物
4-ブロモビフェニル
シアン化銅(I)
準備製品
(S)-5-[(ビフェニル-4-イル)メチル]ピロリジン-2-オン 生産企業
Global( 49)Suppliers
1038924-61-6((S)-5-[(ビフェニル-4-イル)メチル]ピロリジン-2-オン)キーワード:
- 1038924-61-6
- sacubitril
- (S)-5-[(biphenyl-4-yl)Methyl]pyrrolidin-2-one
- (S)-5-([1,1'-biphenyl]-4-ylMethyl)pyrrolidin-2-one
- 2-Pyrrolidinone, 5-([1,1'-biphenyl]-4-ylmethyl)-, (5S)-
- sacubitril ISO 9001：2015 REACH
- (S)-5-[(ビフェニル-4-イル)メチル]ピロリジン-2-オン
- (αR,γS)-γ-[(3-カルボキシ-1-オキソプロピル)アミノ]-α-メチル-4-ビフェニルペンタン酸α-エチル
- (2R,4S)-5-(4-ビフェニリル)-4-[(3-カルボキシプロパノイル)アミノ]-2-メチルペンタン酸1-エチル
- 3-{[(2S,4R)-1-{[1,1'-ビフェニル]-4-イル}-5-エトキシ-4-メチル-5-オキソペンタン-2-イル]カルバモイル}プロパン酸
- 4-[[(1S,3R)-1-(ビフェニル-4-イルメチル)-4-エトキシ-3-メチル-4-オキソブチル]アミノ]-4-オキソブタン酸